Akari Therapeutics Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of October 2016 for Akari Therapeutics Plc, a biopharmaceutical company. The filing primarily addresses significant changes to the composition of the Board of Directors effective October 13, 2016.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation arrangements rather than financial performance.
Material Changes
- Board Appointment: Robert Ward was appointed as a Class A director and Chairman of the Nominating and Governance Committee, effective October 13, 2016.
- Board Resignation: Mark Cohen voluntarily resigned from the Board and its committees (Nominating and Governance, Compensation) effective October 13, 2016, to serve as outside counsel for US intellectual property matters. The resignation was not due to any dispute.
- Committee Reassignment: David Byrne was appointed to the Compensation Committee.
Compensation and Equity Arrangements
- Robert Ward Compensation:
- Cash fees: $36,000 annually for Board service and $10,000 annually for Committee Chairmanship.
- Equity: Initial grant of a ten-year stock option for 1,300,000 ordinary shares (13,000 ADS) at an exercise price of $0.080621 per share ($8.0621 per ADS). Vesting occurs over three years in equal installments.
- Mark Cohen Severance and Equity:
- Acceleration: Outstanding unvested options for 1,028,722 and 1,300,000 ordinary shares were fully vested.
- Additional Grant: New option for 1,300,000 fully vested ordinary shares at $0.080621 per share, exercisable until three months following the 2018 AGM.
- Cash Payments: Quarterly installments totaling $106,750 ($45,750 for the balance of fees through the 2017 AGM and $61,000 for fees from the 2017 to 2018 AGM).
Outlook and Risks
The filing does not contain management commentary on business outlook, risks, contingencies, or unusual items. It states there are no undisclosed arrangements regarding Mr. Ward's appointment.
Investor Verification Checklist
- Verify the impact of the Board composition changes on the company's strategic direction.
- Confirm the dilution effect of the new stock option grants to Mr. Ward and Mr. Cohen (totaling 3,928,722 ordinary shares granted or accelerated).
- Review the company's cash position to ensure it can support the $106,750 severance payment to Mr. Cohen and ongoing director fees.
- Check subsequent filings for the status of Mr. Cohen's role as outside counsel and any related legal fees.